Terms: = Germ cell tumor AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
84 results:
1. T antigen-specific CD8+ T cells associate with pd-1 blockade response in virus-positive Merkel cell carcinoma.
Hansen UK; Church CD; Carnaz Simões AM; Frej MS; Bentzen AK; Tvingsholm SA; Becker JC; Fling SP; Ramchurren N; Topalian SL; Nghiem PT; Hadrup SR
J Clin Invest; 2024 Jan; 134(8):. PubMed ID: 38618958
[TBL] [Abstract] [Full Text] [Related]
2. Frequency and characteristics of immune-related thyroid adverse events in patients with resected stage III/IV melanoma treated with adjuvant pd-1 inhibitors: a national cohort study.
Christensen SK; Winther ML; Laursen IJ; Madsen FS; Brink C; Brix TH; Ellebaek E; Svane IM; Hansen FS; Haslund C; Laursen OK; Schmidt H; Larsen ID; Bastholt L; Ruhlmann CH
Support Care Cancer; 2024 Apr; 32(5):281. PubMed ID: 38598052
[TBL] [Abstract] [Full Text] [Related]
3. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
[TBL] [Abstract] [Full Text] [Related]
4. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
5. CD8+CD103+pd1+TIM3+ T cells in glioblastoma microenvironment correlate with prognosis.
Romagnoli G; D'Alessandris QG; Capone I; Tavilla A; Canini I; Lapenta C; Buccarelli M; Giordano M; Tirelli V; Sanchez M; Fragale A; Giannetti S; Di Bonaventura R; Lauretti L; Biffoni M; Ricci-Vitiani L; Pallini R; Gabriele L
Immunology; 2024 Feb; 171(2):198-211. PubMed ID: 37884280
[TBL] [Abstract] [Full Text] [Related]
6. Independent prognostic biomarker FERMT3 associated with immune infiltration and immunotherapy response in glioma.
Zhuo S; Tang C; Yang L; Chen Z; Chen T; Wang K; Yang K
Ann Med; 2023; 55(2):2264325. PubMed ID: 37795794
[TBL] [Abstract] [Full Text] [Related]
7. A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcome.
Marsiglio J; McPherson JP; Kovacsovics-Bankowski M; Jeter J; Vaklavas C; Swami U; Grossmann D; Erickson-Wayman A; Soares HP; Kerrigan K; Gibson B; Doherty JA; Hyngstrom J; Hardikar S; Hu-Lieskovan S
Front Immunol; 2023; 14():1229823. PubMed ID: 37671166
[TBL] [Abstract] [Full Text] [Related]
8. Recent advances and future challenges of tumor vaccination therapy for recurrent glioblastoma.
Zhao B; Wu J; Li H; Wang Y; Wang Y; Xing H; Wang Y; Ma W
Cell Commun Signal; 2023 Apr; 21(1):74. PubMed ID: 37046332
[TBL] [Abstract] [Full Text] [Related]
9. N7-methylguanosin regulators-mediated methylation modification patterns and characterization of the immune microenvironment in lower-grade glioma.
Maimaiti A; Feng Z; Liu Y; Turhon M; Xie Z; Baihetiyaer Y; Wang X; Kasimu M; Jiang L; Wang Y; Wang Z; Pei Y
Eur J Med Res; 2023 Mar; 28(1):144. PubMed ID: 36998056
[TBL] [Abstract] [Full Text] [Related]
10. β3-adrenergic receptor on tumor-infiltrating lymphocytes sustains IFN-γ-dependent PD-L1 expression and impairs anti-tumor immunity in neuroblastoma.
Bruno G; Nastasi N; Subbiani A; Boaretto A; Ciullini Mannurita S; Mattei G; Nardini P; Della Bella C; Magi A; Pini A; De Marco E; Tondo A; Favre C; Calvani M
Cancer Gene Ther; 2023 Jun; 30(6):890-904. PubMed ID: 36854895
[TBL] [Abstract] [Full Text] [Related]
11. TIMEAS, a promising method for the stratification of testicular germ cell tumor patients with distinct immune microenvironment, clinical outcome and sensitivity to frontline therapies.
Meng J; Gao J; Li X; Gao R; Lu X; Zhou J; Yan F; Wang H; Liu Y; Hao Z; Zhang X; Liang C
Cell Oncol (Dordr); 2023 Jun; 46(3):745-759. PubMed ID: 36823338
[TBL] [Abstract] [Full Text] [Related]
12. Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions.
De Falco V; Suarato G; Napolitano R; Argenziano G; Famiglietti V; Amato A; Servetto A; Bianco R; Formisano L; Terrano V; Esposito A; Giugliano MC; Ciardiello D; Ciardiello F; Napolitano S; Troiani T
Int J Cancer; 2023 Jul; 153(1):133-140. PubMed ID: 36752579
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic significance of pd-1, CTLA-4, CD4, and CD8 expression in olfactory neuroblastoma.
Wu L; Liu H; Liu H
Clin Neuropathol; 2023; 42(2):47-53. PubMed ID: 36708210
[TBL] [Abstract] [Full Text] [Related]
14. Combined pd-1, BRAF and MEK inhibition in BRAF
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
15. Long-term response to camrelizumab in a pretreated metastatic mixed testicular germ-cell tumor patient with co-mutations in DNA damage-repair genes.
Zhang H; Jiang D; Meng E; Zhao M; Niu B
Immunotherapy; 2023 Jan; 15(1):17-25. PubMed ID: 36647794
[TBL] [Abstract] [Full Text] [Related]
16. Dynamics of Melanoma-Associated Epitope-Specific CD8+ T cells in the Blood Correlate With clinical outcome Under pd-1 Blockade.
Gaißler A; Meldgaard TS; Heeke C; Babaei S; Tvingsholm SA; Bochem J; Spreuer J; Amaral T; Wagner NB; Klein R; Meier F; Garbe C; Eigentler TK; Pawelec G; Claassen M; Weide B; Hadrup SR; Wistuba-Hamprecht K
Front Immunol; 2022; 13():906352. PubMed ID: 35874702
[TBL] [Abstract] [Full Text] [Related]
17. Toripalimab (anti-pd-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial.
Lian B; Si L; Chi ZH; Sheng XN; Kong Y; Wang X; Tian H; Li K; Mao LL; Bai X; Tang BX; Yan XQ; Li SM; Zhou L; Dai J; Tang XW; Ran FW; Yao S; Guo J; Cui CL
Ann Oncol; 2022 Oct; 33(10):1061-1070. PubMed ID: 35842199
[TBL] [Abstract] [Full Text] [Related]
18. Wilms tumor reveals DNA repair gene hyperexpression is linked to lack of tumor immune infiltration.
Higgs EF; Bao R; Hatogai K; Gajewski TF
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35705315
[TBL] [Abstract] [Full Text] [Related]
19. Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-pd-1.
McCulloch JA; Davar D; Rodrigues RR; Badger JH; Fang JR; Cole AM; Balaji AK; Vetizou M; Prescott SM; Fernandes MR; Costa RGF; Yuan W; Salcedo R; Bahadiroglu E; Roy S; DeBlasio RN; Morrison RM; Chauvin JM; Ding Q; Zidi B; Lowin A; Chakka S; Gao W; Pagliano O; Ernst SJ; Rose A; Newman NK; Morgun A; Zarour HM; Trinchieri G; Dzutsev AK
Nat Med; 2022 Mar; 28(3):545-556. PubMed ID: 35228752
[TBL] [Abstract] [Full Text] [Related]
20. A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic cells for Metastatic Uveal Melanoma.
Koch EAT; Schaft N; Kummer M; Berking C; Schuler G; Hasumi K; Dörrie J; Schuler-Thurner B
Front Immunol; 2022; 13():785231. PubMed ID: 35185883
[TBL] [Abstract] [Full Text] [Related]
[Next]
